期刊文献+

顶空气相色谱法测定布南色林残留溶剂的含量 被引量:3

Determination of Residual Solvent in Blonanserin by Gas Chromatography with Headspace Sampling
下载PDF
导出
摘要 摘要:目的建立气相色谱法测定布南色林中残留溶剂含量的方法。方法采用6%氰丙基苯基-94%二甲基聚硅氧烷为固定液的毛细管柱(DB-624,0.53mm×30m,3.0μm),程序升温,初始温度50℃,保持5min,以20℃/min的速率升温至200℃,保持5min;氢火焰离子化检测器(FID),检测器温度250℃,进样口温度220℃,载气为氮气,流速2mL/min,进样体积1mL。外标法计算残留溶剂的含量。结果5种有机溶剂进样浓度与峰面积呈良好线性关系,相关系数均大于0.9990,加样回收率在97.6%~102.9%之间。结论此法准确可靠,灵敏度高,可用于布南色林中残留溶剂的测定。 Objective To establish a GC method for the determination of residual solvents in blonanserin. Methods DB-624 chromatographic column (coated with 6 % cyanopropylphenyl-94 % dimethylpolysiloxane, length 30 m, I.D. 0.53 mm, film 3.0μm) was adopted. The column temperature was programmed: kept at 50℃ for 5 min, and then increased by 20℃/min to 200℃ for 5 min, and keot for 5 min. The temperature of FID detector was 250℃ and the temperature of inlet was 220℃. The carrier gas was nitrogen at a flow rate of 2 mL/min. The injection volume was 1 mL. Contents of residual solvents were calculated according to the external standard method. Results The calibration curves of five solvents all showed good linearity in a detected concentration range(r〉0.9990), the range of average recovery was 97.6 %-102.9 %. Conclusion The method was accurate, reliable and sensitive, and can be used for assay of residual organic solvents in blonanserin.
出处 《食品与药品》 CAS 2013年第4期262-264,共3页 Food and Drug
关键词 布南色林 气相色谱法 残留溶剂 blonanserin: gas chromatography residual solvent
  • 相关文献

参考文献1

二级参考文献16

  • 1翟金国,赵靖平,房茂胜.新型非典型抗精神病药临床应用评价[J].中国新药与临床杂志,2006,25(4):296-301. 被引量:42
  • 2OKA M, NODA Y, OCHI Y, et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties[J]. J Pharmacol Exp Ther, 1993, 264(1): 158-165.
  • 3EMMA D, GILLIAN M. Blonanserin: A review of its use in the management of schizophrenia[J]. CNS Drugs, 2010, 24 ( 1 ) : 65- 84.
  • 4MIURA S. Clinical evaluation of blonanserin for schizophrenia : a randomized study comparing blonanserin with risperidone[English abstract] [J]. Jpn J Clin Psychopharmacol, 2008, (11) : 297- 314.
  • 5HADDAD PM, SHARMA SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications[J]. CNS Drugs, 2007, 21 (11): 911-936.
  • 6RICHELSON E. Receptor pharmacology of neuroleptics: relation to clinical effects[J]. J Clin Psychiatry, 1999, 60 Suppl 10: 5- 14.
  • 7OKA M, NODA Y, OCHI Y, et ol. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties[J]. J Pharmacol Exp Ther, 1993, 264 (1): 158-165.
  • 8NODA Y, KURUMIYA S, MIURA Y, et al. Comparative study of 2- (4-ethyl-l-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta [b]pyridine (AD-5423)and haloperidol for their pharmacological activities related to antipsyehotic efficacy and/or adverse side-effects[J]. J Pharmacol Exp Ther, 1993, 265 (2) : 745 -751.
  • 9NAGAI T, NODA Y, UNE T, et al. Effect of AD-5423 on animal models of schizophrenia: phencyelidine-induced behavioural changes in mice[J]. Neuroreport, 2003, 14 (2) : 269-272.
  • 10YOKOTA K, TATEBAYASHI H, MATSUO T, et ol. The effects of neuroleptics on the GABA-induced Cl^- current in rat dorsal root ganglion neurons: differences be tween some neuroleptics[J]. Br J Pharmacol, 2002, 135 (6): 1547-1555.

共引文献13

同被引文献19

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部